Allergy Therapeutics plc has been mentioned in a Form 8.5 (EPT/NON-RI) disclosure by Cavendish Securities plc. The disclosure states that Cavendish Securities plc has an interest in 173,289 ordinary shares of Allergy Therapeutics, representing 0.02% of the total shares. The disclosure also mentions that Cavendish Securities plc has made a sale of 1,649 ordinary shares at a price of 0.03 per share. The disclosure does not include any information about indemnity or option arrangements, agreements, arrangements, or understandings relating to options or derivatives. No supplemental form or attachments were included in the disclosure. The disclosure was made on September 15, 2023, and the contact person for further information is Matthew Judge, with a telephone number of 020 7397 8986.